Visceral Fat and Inflammation: Risks and Remedies

Visceral fat and inflammation are closely linked processes that together drive some of the most serious chronic health conditions seen in UK adults today. Unlike the fat you can pinch beneath the skin, visceral fat sits deep within the abdominal cavity, surrounding vital organs, and behaves like an active endocrine tissue. It continuously releases pro-inflammatory molecules that disrupt normal cellular function throughout the body. Understanding how visceral fat fuels inflammation, which conditions it raises the risk of, and what you can do to reduce it is essential for protecting your long-term metabolic and cardiovascular health.

What is visceral fat and why does it cause inflammation?

Visceral fat causes inflammation by secreting pro-inflammatory cytokines such as TNF-alpha and IL-6, recruiting macrophages into fat tissue, and draining free fatty acids directly into the liver via the portal vein, creating a self-reinforcing cycle of systemic inflammation.

Visceral fat is metabolically active adipose tissue stored deep within the abdominal cavity, surrounding organs such as the liver, pancreas and intestines, and it drives inflammation by releasing pro-inflammatory signalling molecules called cytokines. Unlike subcutaneous fat, which sits just beneath the skin, visceral fat behaves almost like an endocrine organ. It continuously secretes substances including tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and reduces the output of the anti-inflammatory adipokine adiponectin.^[1][2] IL-6 released from adipose tissue and recruited immune cells travels to the liver, where it stimulates hepatic production of C-reactive protein (CRP), a key marker of systemic inflammation.^[1][2] These processes together promote a state of low-grade, chronic systemic inflammation.

The mechanism begins at the cellular level. Visceral fat cells (adipocytes) become enlarged as fat accumulates, and this enlargement triggers the recruitment of immune cells called macrophages into the fat tissue. These macrophages release further inflammatory mediators, creating a self-reinforcing cycle. Free fatty acids released by visceral fat, along with inflammatory molecules, drain directly into the liver via the portal vein, amplifying their systemic effects.^[1][19]

It is important to note that not everyone with excess body weight carries the same proportion of visceral fat. Genetic factors, sex hormones, age and lifestyle all influence where fat is deposited. Men and postmenopausal women tend to accumulate more visceral fat relative to total body fat, which partly explains differences in metabolic risk between groups.^[16][17] Even individuals with a body mass index (BMI) in the normal range can carry clinically significant amounts of visceral fat, a pattern sometimes described as metabolically obese, normal weight.

How does chronic inflammation from visceral fat affect your health?

Chronic inflammation from visceral fat impairs multiple organ systems, most significantly causing insulin resistance, fatty liver disease, atherosclerosis, endothelial dysfunction and increased risk of hypertension, heart attack and stroke.

Chronic inflammation driven by visceral fat gradually impairs the function of multiple organ systems, increasing the risk of serious long-term disease. The persistent elevation of inflammatory cytokines disrupts normal cellular signalling throughout the body. One of the earliest and most significant consequences is insulin resistance, in which cells in the muscles, liver and fat tissue respond less effectively to insulin, forcing the pancreas to produce progressively more of the hormone to maintain blood glucose control.

The liver is particularly vulnerable. Inflammatory signals and free fatty acids arriving via the portal vein promote the accumulation of fat within liver cells, a process that can progress from simple steatosis (fatty liver) to non-alcoholic steatohepatitis (NASH) and, in some cases, cirrhosis. Simultaneously, visceral fat-associated metabolic changes promote the production of small, dense low-density lipoprotein (LDL) particles and raise triglyceride levels, both of which contribute to atherosclerosis, the build-up of plaques within arterial walls.^[1][2]

Inflammation also affects the cardiovascular system more directly. Elevated CRP and IL-6 levels are associated with endothelial dysfunction, meaning the inner lining of blood vessels becomes less able to regulate blood flow and clotting. Over time, this is associated with increased risk of hypertension, heart attack and stroke. There is also emerging evidence linking chronic low-grade inflammation to brain health, with some research suggesting associations with cognitive decline and depression, though the precise mechanisms in humans are still being investigated and causality has not been established. The cumulative effect of these processes means that visceral fat and inflammation together represent a significant driver of premature morbidity.

Which health conditions are linked to visceral fat and inflammation?

Excess visceral fat is strongly associated with type 2 diabetes, cardiovascular disease, NAFLD (MASLD), certain cancers including colorectal and endometrial, obstructive sleep apnoea, PCOS and gout, often clustering as metabolic syndrome.

Excess visceral fat and the chronic inflammation it generates are strongly associated with a broad range of serious health conditions, including type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, certain cancers and obstructive sleep apnoea. The strength of evidence varies by condition: causal pathways are best established for insulin resistance, type 2 diabetes and metabolic liver disease, while for other conditions such as certain cancers and obstructive sleep apnoea the associations are robust but the mechanisms are more complex.

Type 2 diabetes is among the most well-established associations. Insulin resistance driven by visceral fat inflammation is a central feature of the condition, and reducing visceral fat through lifestyle change or medical intervention is known to improve glycaemic control. Cardiovascular disease risk is similarly elevated, with visceral adiposity strongly associated with adverse cardiac events even after adjusting for traditional risk factors such as total cholesterol and blood pressure.

Non-alcoholic fatty liver disease (NAFLD), now increasingly termed metabolic dysfunction-associated steatotic liver disease (MASLD), affects a substantial proportion of adults in the UK and is closely linked to visceral adiposity. Certain cancers, including colorectal, endometrial and postmenopausal breast cancer, are also associated with excess visceral fat, likely through inflammatory and hormonal mechanisms.^[5][20] Obstructive sleep apnoea, polycystic ovary syndrome (PCOS) and gout are further conditions where visceral fat and inflammation play a recognised role.

These conditions frequently cluster together, a pattern recognised clinically as metabolic syndrome. NICE guidance on obesity and related conditions acknowledges the importance of addressing central adiposity as part of comprehensive risk reduction, rather than focusing on weight alone.

How can you measure visceral fat at home or with your GP?

Waist circumference is the most practical proxy for visceral fat; NICE NG219 recommends thresholds of 94 cm in men and 80 cm in women for white European adults, with lower thresholds advised for South Asian and East Asian populations.

Waist circumference is the most practical and widely recommended proxy measure for visceral fat, and NICE guidance (NG219) supports its use alongside BMI to assess metabolic risk. For white European adults, a waist measurement above 94 cm in men or above 80 cm in women is associated with increased health risk, with measurements above 102 cm in men and 88 cm in women indicating substantially higher risk. To measure accurately at home, use a flexible tape measure placed midway between the lower rib and the top of the hip bone, breathing out gently before taking the reading, as described in NHS guidance on measuring your waist.

Waist-to-height ratio is another accessible tool. A ratio above 0.5 (meaning your waist circumference is more than half your height) is considered a marker of excess central adiposity across a range of ethnicities, and is referenced in NICE NG219.^[6][11] It is worth noting that standard BMI and waist thresholds may underestimate risk in people of South Asian, Chinese and other East Asian backgrounds, where metabolic complications can occur at lower measurements. NICE and NHS guidance acknowledges these differences, and lower BMI thresholds (approximately 23 kg/m2 for overweight and 27.5 kg/m2 for obesity) are recommended for South Asian, Chinese and other East Asian populations.

For more precise quantification, imaging techniques are available. Dual-energy X-ray absorptiometry (DEXA) scanning and magnetic resonance imaging (MRI) can distinguish visceral from subcutaneous fat, but these are not routinely used in primary care. Some GP practices and specialist clinics offer bioelectrical impedance analysis (BIA), which estimates body composition including visceral fat; however, accuracy varies considerably between devices, and consumer visceral fat scores from home scales are not well validated and should not be used as the basis for clinical decisions. If you are concerned about your visceral fat levels, your GP can assess your waist circumference, calculate your BMI, and arrange blood tests to check for associated metabolic abnormalities such as raised fasting glucose, triglycerides or liver enzymes.

What lifestyle changes actually reduce visceral fat and lower inflammation?

A combination of at least 150 minutes of moderate aerobic exercise per week, a Mediterranean-style diet, reduced alcohol intake and good sleep quality are the most evidence-based strategies for reducing visceral fat and systemic inflammation.

Regular physical activity, particularly a combination of aerobic exercise and resistance training, is one of the most effective evidence-based strategies for reducing visceral fat and lowering systemic inflammation. Research shows that aerobic exercise such as brisk walking, cycling or swimming can reduce visceral adiposity even in the absence of significant overall weight loss.^[13][14] NHS guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults, alongside muscle-strengthening activities on two or more days.^[8]

Dietary changes are equally important. A diet rich in vegetables, fruit, wholegrains, legumes, oily fish and unsaturated fats, broadly consistent with a Mediterranean-style pattern and aligned with the NHS Eatwell Guide, is associated with reduced visceral fat and lower inflammatory markers. Conversely, diets high in ultra-processed foods, refined carbohydrates, added sugars and saturated fats are associated with visceral fat accumulation and inflammation. Reducing alcohol intake is also relevant, as alcohol contributes to liver fat deposition and raises inflammatory markers. The UK Chief Medical Officers advise drinking no more than 14 units of alcohol per week, spread over three or more days, with several alcohol-free days each week.^[9][10]

Sleep quality and stress management are often overlooked but clinically meaningful. Chronic sleep deprivation and elevated cortisol from psychological stress both promote visceral fat deposition through hormonal mechanisms. NHS guidance indicates that most adults need between six and nine hours of sleep per night; aiming for good-quality sleep within this range and incorporating stress-reduction strategies such as mindfulness or structured relaxation can support metabolic health.

For individuals who have not achieved sufficient benefit from lifestyle measures alone, medical management may be appropriate. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options can be discussed alongside lifestyle guidance. Smoking cessation is also strongly recommended, as smoking is independently associated with greater visceral fat deposition and heightened inflammatory burden.^[21]

When should you speak to a doctor about visceral fat and inflammation?

Speak to your GP if your waist circumference exceeds risk thresholds, you have a family history of diabetes or cardiovascular disease, or you experience symptoms such as unexplained fatigue, increased thirst, jaundice or sleep apnoea.

You should speak to your GP about visceral fat and inflammation if your waist circumference exceeds the risk thresholds described above, if you have a family history of type 2 diabetes or cardiovascular disease, or if you have already been diagnosed with a condition associated with metabolic syndrome. Early assessment allows your GP to arrange relevant blood tests, including fasting glucose, HbA1c, lipid profile and liver function tests, and to discuss whether further investigation or intervention is warranted.

Certain symptoms should prompt a more timely conversation with your GP rather than waiting for a routine appointment. These include:

• Unexplained fatigue or increased thirst, which may suggest impaired glucose regulation

• Yellowing of the skin or eyes (jaundice), persistent right upper quadrant discomfort or unexplained weight loss, which may indicate liver involvement and warrant prompt assessment

• Elevated blood pressure identified at a pharmacy or home monitor

• Snoring or witnessed pauses in breathing during sleep, which may indicate obstructive sleep apnoea

It is worth noting that MASLD is often asymptomatic in its early stages, so the absence of symptoms does not rule out liver involvement; blood tests and, where indicated, fibrosis risk assessment tools are the appropriate route to evaluation.

If you experience chest pain, sudden breathlessness or other symptoms suggesting a cardiac event, call 999 immediately. For urgent advice that does not require an emergency response, NHS 111 is available around the clock.

Your GP may refer you to a specialist dietitian, a structured weight management programme, or a specialist metabolic clinic depending on your individual circumstances and local Integrated Care Board (ICB) commissioning pathways. If a medicine is being considered to support weight management, your prescriber will review your full medical history, current medications and any contraindications before making a recommendation. Suspected side effects from any prescribed medicine can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Open and honest conversations with your healthcare team about visceral fat and its consequences are an important step towards reducing your long-term health risk.

Scientific References

1. Visceral fat and metabolic inflammation: the portal theory.
2. Reappraisal of Adipose Tissue Inflammation in Obesity. Advances in Experimental Medicine and Biology.
3. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arteriosclerosis, Thrombosis, and Vascular Biology.
4. Visseral Lipectomy Improves Metabolic Syndrome Parameters and Adipokines in a Rat Model of Metabolic Syndrome Induced by Monosodium Glutamate. Aesthetic Plastic Surgery.
5. The association of body fat composition with risk of breast cancer.
6. Overweight and obesity management (NG246): Identifying and assessing overweight, obesity and central adiposity.
7. NG246 Appendix A1: Summary of evidence from surveillance – BMI thresholds for Asian populations.
8. Physical activity guidelines for adults aged 19 to 64.
9. Drink less alcohol – Better Health.
10. Delivering Better Oral Health: Chapter 12 – Alcohol (UK Chief Medical Officers' guidance).
11. Calculate your waist to height ratio.
12. Non-alcoholic fatty liver disease (NAFLD).
13. A dose-response relation between aerobic exercise and visceral fat reduction.
14. Aerobic Exercise and Weight Loss in Adults: A Systematic Review and Dose-Response Meta-Analysis. JAMA Network Open.
15. Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Assessed 5- and 10-Year Follow-Up After 2 Clinical Trials. Circulation.
16. Sex Differences in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Journal of Clinical and Experimental Hepatology.
17. Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan. Frontiers in Endocrinology.
18. Adiposity-Metabolic Discordance Identifies Cardiometabolically Heterogeneous Profiles in Normal-Weight Adults. Medical Sciences (Basel).
19. The role of visceral and subcutaneous adipose tissue fatty acid composition in liver pathophysiology associated with NAFLD. Adipocyte.
20. Biomolecular basis related to inflammation in the pathogenesis of endometrial cancer. European Review for Medical and Pharmacological Sciences.
21. Smoking inhibits visceral fat accumulation in Turkish women [markers of insulin resistance and inflammation independently associated with visceral fat].

Frequently Asked Questions